Tag Archives: CellMax

Companies Enter Partnership for Blood Test to Detect Colorectal Cancer and Pre-Cancer

SUNNYVALE, Calif., and ROSWELL, Ga.—CellMax Life, a molecular diagnostics company with proprietary technology for pre-cancer and cancer detection blood tests, and Sebela Pharmaceuticals, a market leader in gastroenterology, recently announced the closing of a strategic development and commercial collaboration agreement, as well as CellMax’s Series C financing. The financing will be used to accelerate the clinical development of CellMax’s multimodal ...

Read More »